Health care investors are moving out of sectors that could be hit with federal funding cuts, or become vilified in the media.
Contract research organizations (CROs) are hot targets this year. The heavy demand by pharma and biotech companies is attracting large private equity buyers.
Patheon N.V., formerly Patheon, Inc., has been acquired by Thermo Fisher Scientific for $7.2 billion. This deal marks the largest year-to-date in the contract development and manufacturing market.
The CRO market is a favorite of private equity investors, and M&A activity has been strong in the first half of 2017.
Private equity firms are taking big stakes in contract research organizations in 2017.
Bracket, a clinical trial technology provider, has changed hands several times in recent years.
Quotient Clinical, a clinical research organization based in the United Kingdom, has made two rapid-fire acquisitions in the United States in February 2017.
Deals for contract research organizations (CROs) surged 157% in 2016.